Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR‐1210), a novel anti‐PD‐1 antibody
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR‐1210), a novel anti‐PD‐1 antibody
Authors
Keywords
-
Journal
Thoracic Cancer
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-04-24
DOI
10.1111/1759-7714.13083
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma
- (2018) Jing Huang et al. CLINICAL CANCER RESEARCH
- Safety and Antitumor Activity of the Anti–Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma
- (2018) Toshihiko Doi et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
- (2017) Toshihiro Kudo et al. LANCET ONCOLOGY
- Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
- (2017) Stefan Diem et al. LUNG CANCER
- Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
- (2017) Stephen J. Bagley et al. LUNG CANCER
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
- (2016) Benjamin Weide et al. CLINICAL CANCER RESEARCH
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- Small data sets to develop and validate prognostic models are problematic
- (2016) Gary S. Collins et al. EUROPEAN JOURNAL OF CANCER
- Use of LDH and autoimmune side effects to predict response to ipilimumab treatment
- (2016) J Dick et al. Immunotherapy
- Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study
- (2016) Jing Huang et al. Journal of Thoracic Oncology
- Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
- (2016) Yoshio Nakamura et al. Oncotarget
- The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma
- (2016) Leila Khoja et al. Cancer Medicine
- Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
- (2015) P F Ferrucci et al. BRITISH JOURNAL OF CANCER
- High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma
- (2015) J. Zaragoza et al. BRITISH JOURNAL OF DERMATOLOGY
- Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab
- (2015) S. Valpione et al. EUROPEAN JOURNAL OF CANCER
- Recent Advances From Basic and Clinical Studies of Esophageal Squamous Cell Carcinoma
- (2015) Shinya Ohashi et al. GASTROENTEROLOGY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with esophageal squamous cell carcinoma
- (2015) Xiao-li Wei et al. TUMOR BIOLOGY
- Irinotecan plus fluorouracil-based regimen as second or third-line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma
- (2015) Xi Wang et al. Thoracic Cancer
- Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab
- (2015) Jon Bjoern et al. OncoImmunology
- Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
- (2014) Ester Simeone et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
- (2013) J. Delyon et al. ANNALS OF ONCOLOGY
- Epidemiology of Esophageal Cancer in Japan and China
- (2013) Yingsong Lin et al. JOURNAL OF EPIDEMIOLOGY
- Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma
- (2013) Sofie Wilgenhof et al. JOURNAL OF IMMUNOTHERAPY
- Oesophageal carcinoma
- (2013) Arjun Pennathur et al. LANCET
- A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy
- (2012) Jing Huang et al. MEDICAL ONCOLOGY
- Barrett's esophagus-related diseases remain uncommon in China
- (2011) Qin HUANG et al. Journal of Digestive Diseases
- Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
- (2010) Geoffrey Y. Ku et al. CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now